Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5215551 | 0.80 | SMN1; SMN2 (0.37) | SMN1; SMN2KMT2ACA1CA2CA14 | |
| SCHEMBL19294661 | 0.79 | — | — | |
| SCHEMBL19294655 | 0.79 | — | — | |
| SCHEMBL19294657 | 0.79 | — | — | |
| SCHEMBL23220986 | 0.78 | CA14 (0.33) | SMN1; SMN2KMT2ACA1CA2CA14 | |
| SCHEMBL28393656 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2KMT2ACA1CA2 | |
| SCHEMBL2379201 | 0.75 | CHRNB2 (0.33) | SMN1; SMN2 | |
| SCHEMBL9069054 | 0.74 | ATM (0.47) | SMN1; SMN2TSHR | |
| SCHEMBL5606099 | 0.71 | SMN1; SMN2 (0.39) | SMN1; SMN2KMT2ACA1CA2CA14 | |
| SCHEMBL21076339 | 0.71 | CA1 (0.30) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| US-9586893-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals (US) | 2017-03-07 | — | — | US | disclosed |
| US-9227965-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140228574-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-14 | — | — | US | disclosed |
| US-20130005976-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228574-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | CPN1, CMA1, CYP51A1 | SMN1; SMN2 4662/4885KMT2A 4366/4885CA1 117/4885 |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | HAVCR2, RNASE1, CPB1 | SMN1; SMN2 4090/4885KMT2A 4558/4885CA1 822/4885 |
| US-20130005976-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | HAVCR2, RNASE1, CPB1 | SMN1; SMN2 4090/4885KMT2A 4558/4885CA1 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.